106 related articles for article (PubMed ID: 2733069)
1. A study of CEA, CA 19-9 and CA 125 in biliary tract diseases.
Ker CG; Wu CC; Chen JS; Hou MF; Lee KT; Sheen PC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1989 Feb; 5(2):107-13. PubMed ID: 2733069
[TBL] [Abstract][Full Text] [Related]
2. Carcinoembryonic antigen and blood group-related carbohydrate antigens in glycoproteins in human bile in hepatolithiasis. Japanese Study Group of Hepatolithiasis.
Sasaki M; Morita T; Hoso M; Nakanuma Y; Tanimura H
Hepatology; 1996 Feb; 23(2):258-63. PubMed ID: 8591850
[TBL] [Abstract][Full Text] [Related]
3. Elevation of carcinoembryonic antigen related to biliary malignancy in hepatolithiasis.
Ker CG; Sheen PC; Chien CH; Wu CC
Surg Today; 1993; 23(6):496-9. PubMed ID: 8358193
[TBL] [Abstract][Full Text] [Related]
4. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.
Chen CY; Shiesh SC; Tsao HC; Lin XZ
Hepatogastroenterology; 2002; 49(45):616-20. PubMed ID: 12063953
[TBL] [Abstract][Full Text] [Related]
5. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
8. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
9. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.
Kim YT; Byun JS; Kim J; Jang YH; Lee WJ; Ryu JK; Kim SW; Yoon YB; Kim CY
Hepatogastroenterology; 2003; 50(49):8-12. PubMed ID: 12629979
[TBL] [Abstract][Full Text] [Related]
10. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
[TBL] [Abstract][Full Text] [Related]
11. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma.
Ker CG; Chen JS; Lee KT; Sheen PC; Wu CC
J Gastroenterol Hepatol; 1991; 6(5):505-8. PubMed ID: 1657243
[TBL] [Abstract][Full Text] [Related]
12. The role of bile carcinoembryonic antigen in diagnosing bile duct cancer.
Joo KR; Kim DH; Park JH; Bang SJ; Shin JW; Park NH; Park JH
J Korean Med Sci; 2003 Dec; 18(6):855-8. PubMed ID: 14676443
[TBL] [Abstract][Full Text] [Related]
13. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
[TBL] [Abstract][Full Text] [Related]
14. [Biliary carcinoembryonic antigen, non-specific cross-reacting antigen and biliary glycoprotein--their analysis and clinical aspects].
Yano Y
Nihon Geka Gakkai Zasshi; 1986 Nov; 87(11):1432-42. PubMed ID: 3537682
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical study of cancer-associated carbohydrate antigens in carcinoma of the biliary tract].
Sasaki R
Nihon Geka Gakkai Zasshi; 1989 Dec; 90(12):1976-88. PubMed ID: 2560529
[TBL] [Abstract][Full Text] [Related]
16. Cell kinetic analyses and expression of carcinoembryonic antigen, carbohydrate antigen 19-9 and DU-PAN-2 in hyperplastic, pre-neoplastic and neoplastic lesions of intrahepatic bile ducts in livers with hepatoliths.
Terada T; Nakanuma Y
Virchows Arch A Pathol Anat Histopathol; 1992; 420(4):327-35. PubMed ID: 1348889
[TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen (CEA) and CEA-related substances in the bile of patients with biliary diseases.
Uchino R; Kanemitsu K; Obayashi H; Hiraoka T; Miyauchi Y
Am J Surg; 1994 Mar; 167(3):306-8. PubMed ID: 8160902
[TBL] [Abstract][Full Text] [Related]
19. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
20. Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma.
Wang P; He Y; Ma X; Sun B; Huang B; Zhu C; Liu Y
Med Sci Monit; 2015 Oct; 21():2943-9. PubMed ID: 26423666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
